iRhythm Technologies, Inc.

How big is iRhythm Technologies, Inc.?

As of Jun 18, iRhythm Technologies, Inc. has a market capitalization of $4.63 billion, with net sales of $618.59 million and a net profit of -$98.32 million over the latest four quarters. The company reported shareholder's funds of $90.91 million and total assets of $931.45 million as of Dec 24.

Market Cap: As of Jun 18, iRhythm Technologies, Inc. has a market capitalization of 4,627.57 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, iRhythm Technologies, Inc. reported net sales of 618.59 million and a net profit of -98.32 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 90.91 million and total assets of 931.45 million.

What does iRhythm Technologies, Inc. do?

iRhythm Technologies, Inc. is a digital health company specializing in biosensor technology and analytics for patient data, with a market cap of approximately $4.63 billion. As of March 2025, it reported net sales of $159 million and a net loss of $31 million.

Overview:<BR>iRhythm Technologies, Inc. is a digital health company that develops and commercializes solutions integrating biosensor technology, patient data, analytics, and medical expertise, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 159 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -31 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 4,627.57 Million (Small Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 1.65 <BR>Return on Equity: -76.24% <BR>Price to Book: 53.40 <BR><BR>Contact Details:<BR>Address: 650 Townsend St Ste 500, SAN FRANCISCO CA: 94103-6227 <BR>Tel: 1 415 6325700 <BR>Website: https://www.irhythmtech.com/

Should I buy, sell or hold iRhythm Technologies, Inc.?

Who are in the management team of iRhythm Technologies, Inc.?

As of March 2022, the management team of iRhythm Technologies, Inc. consists of independent directors, including Mr. Abhijit Talwalkar (Chairman), Mr. Bruce Bodaken, Ms. Renee Budig, Dr. Cathleen Noel Merz, Mr. Mark Rubash, and Mr. Raymond Scott. They provide governance and oversight for the company.

As of March 2022, the management team of iRhythm Technologies, Inc. includes the following individuals:<BR><BR>- Mr. Abhijit Talwalkar, Independent Chairman of the Board<BR>- Mr. Bruce Bodaken, Independent Director<BR>- Ms. Renee Budig, Independent Director<BR>- Dr. Cathleen Noel Merz, Independent Director<BR>- Mr. Mark Rubash, Independent Director<BR>- Mr. Raymond Scott, Independent Director<BR><BR>This team comprises a group of independent directors who provide governance and oversight for the company.

Is iRhythm Technologies, Inc. overvalued or undervalued?

As of February 15, 2017, iRhythm Technologies, Inc. is considered risky and overvalued due to its high Price to Book Value, negative EV to EBITDA, and poor ROE, despite a strong recent return, as its long-term performance significantly lags behind the S&P 500.

As of 15 February 2017, the valuation grade for iRhythm Technologies, Inc. moved from does not qualify to risky. The company appears to be overvalued given its high Price to Book Value of 54.03, a negative EV to EBITDA of -95.35, and a troubling ROE of -76.24%. In comparison, peers such as Globus Medical, Inc. and CONMED Corp. show more attractive valuations with P/E ratios of 18.37 and 19.96, respectively.<BR><BR>Despite a strong year-to-date return of 95.63% compared to the S&P 500's 12.22%, the longer-term performance reveals a concerning trend, with a 5-year return of -24.40% against the S&P 500's 96.61%. This indicates that while recent performance may seem promising, the overall valuation metrics suggest that iRhythm Technologies, Inc. is not justified at its current price level.

Is iRhythm Technologies, Inc. technically bullish or bearish?

As of October 24, 2025, iRhythm Technologies, Inc. has a mildly bullish trend supported by monthly bullish signals, despite some weekly bearish indicators, and has outperformed the S&P 500 year-to-date with a 100.30% return, though it has underperformed over the past five years with a -17.96% return.

As of 24 October 2025, the technical trend for iRhythm Technologies, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by monthly bullish signals in MACD, Bollinger Bands, KST, and OBV, despite weekly indicators showing mild bearishness in MACD and KST. The daily moving averages are bullish, supporting the overall mildly bullish trend. <BR><BR>In terms of performance, the company has significantly outperformed the S&P 500 year-to-date with a return of 100.30% compared to the S&P 500's 15.47%. However, over the past five years, the stock has underperformed with a return of -17.96% versus the S&P 500's 95.99%.